Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - atorvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - gabapentin -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - latanoprost -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - paracetamol -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - quinapril hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sertraline hydrochloride -

United States - English - NLM (National Library of Medicine)

pfizer manufacturing belgium nv - tozinameran (unii: 5085zfp6sj) (tozinameran - unii:5085zfp6sj), famtozinameran (unii: jsv288q5cv) (famtozinameran - unii:jsv288q5cv) - pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5) is authorized for use under an emergency use authorization (eua) for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in individuals 5 years of age and older. this eua prescribing information pertains only to pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5), hereafter referred to as pfizer-biontech covid-19 vaccine, bivalent, supplied in a multiple dose vial with an orange cap and a label with an orange border, which is authorized for use in individuals 5 through 11 years of age. the vial labels state: age 5y to <12y. the carton labels state: for age 5 years to <12 years. do not administer pfizer-biontech covid-19 vaccine, bivalent to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the pfizer-biontech covid-19 vaccine or the pfizer-biontech covid-19 vaccine, bivalent [

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - coated tablets - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ondansetron hydrochloride dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ondansetron hydrochloride dihydrate -